KMID : 1100720230430040364
|
|
Annals of Laboratory Medicine 2023 Volume.43 No. 4 p.364 ~ p.374
|
|
Impact of Low-Level Donor-Specific Anti-HLA Antibody on Posttransplant Clinical Outcomes in Kidney Transplant Recipients
|
|
Lee Ha-Eun
Lee Han-Bi Eum Sang-Hun Ko Eun-Jeong Min Ji-Won Oh Eun-Jee Yang Chul-Woo Chung Byung-Ha
|
|
Abstract
|
|
|
Background: The clinical significance of low-level donor-specific anti-HLA antibody (low-DSA) remains controversial. We investigated the impact of low-DSA on posttransplant clinical outcomes in kidney transplant (KT) recipients.
Methods: We retrospectively reviewed 1,027 KT recipients, namely, 629 living donor KT (LDKT) recipients and 398 deceased donor KT (DDKT) recipients, in Seoul St. Mary¡¯s Hospital (Seoul, Korea) between 2010 and 2018. Low-DSA was defined as a positive anti-HLA-DSA result in the Luminex single antigen assay (LABScreen single antigen HLA class I - combi and class II - group 1 kits; One Lambda, Canoga Park, CA, USA) but a negative result in a crossmatch test. We compared the incidence of biopsy-proven allograft rejection (BPAR), changes in allograft function, allograft survival, patient survival, and posttransplant infections between subgroups according to pretransplant low-DSA.
Results: The incidence of overall BPAR and T cell-mediated rejection did not differ between the subgroups. However, antibody-mediated rejection (ABMR) developed more frequently in patients with low-DSA than in those without low-DSA in the total cohort and the LDKT and DDKT subgroups. In multivariate analysis, low-DSA was identified as a risk factor for ABMR development. Its impact was more pronounced in DDKT (odds ratio [OR]: 9.60, 95% confidence interval [CI]: 1.79?51.56) than in LDKT (OR: 3.76, 95% CI: 0.99?14.26) recipients. There were no significant differences in other outcomes according to pretransplant low-DSA.
Conclusions: Pretransplant low-DSA has a significant impact on the development of ABMR, and more so in DDKT recipients than in LDKT recipients, but not on long-term outcomes.
|
|
KEYWORD
|
|
Donor-specific anti-HLA antibody, Donor-specific antibody, Kidney transplantation, Rejection, Graft survival, Infection
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|
|